The online hub for digital CME and CE courses
The ONA Forum consultants answer your questions
View articles about patient-focused care
Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, according to a new study. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an abnormal physical examination or an abnormal blood test at the time of relapse, researchers say.
The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Nurses play a critical role in promoting safety for patients with indolent forms of non-Hodgkin lymphoma receiving radioimmunotherapy, according to research presented at the ONS 38th Annual Congress.
An international research team has identified a new type of deadly intestinal lymphoma that is particularly common in Asia. The team also developed a new diagnostic test to accurately identify the disease.
Packaging crystalline arsenic particles in a bubble of fat helps deliver the drug into lymphoma cells without damaging the ovaries.
Researchers at Weill Cornell Medical College report that it is possible to shut down the master regulatory transcription factor Blc6 in DLBCL while not affecting its vital function in the T cells and macrophages needed to support a healthy immune system.
Molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation have been identified. This animal study shows that X-rays or gamma rays alter the levels of certain molecules called microRNA (miRNA) in the blood in a predictable way.
Persons who have undergone cytotoxic chemotherapy for certain cancers, notably non-Hodgkin lymphoma, may develop acute myeloid leukemia.
High doses of vorinostat (suberoylanilide hydroxamic acid) in combination with another round of commonly used second-line drugs produced a 70% response rate in patients with aggressive, relapsed lymphoma, including complete elimination of lymphoma cells in several patients.
Lymphoma can be starved to death by depriving it of what appears to be a favorite food: HDL cholesterol. A new nanoparticle appears to the cancerous lymphoma cell like a preferred meal of natural HDL.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
